SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IN_GOD_I_TRUST who wrote (443)8/19/1997 9:24:00 AM
From: Apple Jacks   of 998
 
Hi everyone,

I am new to Silicon Investor, so this is my first entry. However, I have been following the Cephalon thread with great interest the last couple of months.

Personally, I think that the drug will get its approval in November. With the Regeneron drug falling on its face earlier in the year and the political pressure being applied on the commissioner-less FDA, it would appear that the approving the drug would be of little harm (the FDA may apply certain conditions or restrictions on the approval).

I expect the stock to slowly turnaround as we approach the November 11 date. I had purchased sone September call options prior to the the August 11 date. Unfortunately, because of the extension the options have no chance of being in the money. Not much harm done since it only cost me $200 for gambling on a potential $3,000 gain if Cephalon hit $30 (with approval).

I will be looking to purchase some November calls in the next several weeks (too expensive now).

I think Cephalon is certainly worth a small gamble.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News